Figure 1 | Scientific Reports

Figure 1

From: A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications

Figure 1

Study Selection. Studies were selected from various literature databases, identifying clinical trials with fluvoxamine for COVID-19. Studies were split into all studies and randomized placebo-controlled studies. *Oskotsky et al., retrospective trial included all SSRI drugs and combined fluvoxamine with fluoxetine and, therefore, was excluded from the meta-analysis. § Studies with no deaths in either group (fluvoxamine or control) were not entered into the COVID-19 mortality meta-analysis. †Only one placebo-controlled study of fluvoxamine in COVID-19 had deaths in either group (fluvoxamine or control), so the meta-analysis could not be carried out.

Back to article page